WallStreetZenWallStreetZen

NASDAQ: DYN
Dyne Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DYN

Based on 6 analysts offering 12 month price targets for Dyne Therapeutics Inc

Min Forecast
$24.00-6.61%
Avg Forecast
$37.50+45.91%
Max Forecast
$50.00+94.55%

Should I buy or sell DYN stock?

Based on 7 analysts offering ratings for Dyne Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 42.86%
Buy
3 analysts 42.86%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DYN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DYN as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their DYN stock forecasts and price targets.

DYN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-31
lockedlocked$00.00+00.00%2026-07-30
lockedlocked$00.00+00.00%2026-06-26
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-05-13
Chardan Capital
Top 3%
98
Strong BuyMaintains$38.00+47.86%2026-03-09
HC Wainwright & Co.
Top 26%
75
BuyMaintains$50.00+94.55%2026-03-03

1 of 1

Forecast return on equity

Is DYN forecast to generate an efficient return?

Company
-5.91%
Industry
46.6%
Market
167.87%
DYN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DYN forecast to generate an efficient return on assets?

Company
-4.17%
Industry
37.27%
DYN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DYN earnings per share forecast

What is DYN's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
-$3.10
Avg 2 year Forecast
-$2.95
Avg 3 year Forecast
-$2.36

DYN revenue forecast

What is DYN's revenue in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$63.8M
Avg 3 year Forecast
$287.6M

DYN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DYN$25.70$37.50+45.91%Strong Buy
EWTX$44.17$49.25+11.50%Buy
ACAD$28.24$34.15+20.94%Strong Buy
MANE$112.71$150.17+33.23%Strong Buy
CELC$92.00$160.57+74.53%Strong Buy
View Top Biotech Stocks

Dyne Therapeutics Stock Forecast FAQ

Is Dyne Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: DYN) stock is to Strong Buy DYN stock.

Out of 7 analysts, 3 (42.86%) are recommending DYN as a Strong Buy, 3 (42.86%) are recommending DYN as a Buy, 1 (14.29%) are recommending DYN as a Hold, 0 (0%) are recommending DYN as a Sell, and 0 (0%) are recommending DYN as a Strong Sell.

If you're new to stock investing, here's how to buy Dyne Therapeutics stock.

What is DYN's earnings growth forecast for 2026-2028?

(NASDAQ: DYN) Dyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.68%.

Dyne Therapeutics's earnings in 2026 is -$519,406,000.On average, 18 Wall Street analysts forecast DYN's earnings for 2026 to be -$578,222,974, with the lowest DYN earnings forecast at -$633,219,798, and the highest DYN earnings forecast at -$545,112,832. On average, 16 Wall Street analysts forecast DYN's earnings for 2027 to be -$550,584,503, with the lowest DYN earnings forecast at -$711,914,744, and the highest DYN earnings forecast at -$445,110,118.

In 2028, DYN is forecast to generate -$440,889,649 in earnings, with the lowest earnings forecast at -$803,420,495 and the highest earnings forecast at -$166,671,190.

What is DYN's revenue growth forecast for 2026-2028?

(NASDAQ: DYN) Dyne Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.

Dyne Therapeutics's revenue in 2026 is $0.On average, 17 Wall Street analysts forecast DYN's revenue for 2026 to be $0, with the lowest DYN revenue forecast at $0, and the highest DYN revenue forecast at $0. On average, 15 Wall Street analysts forecast DYN's revenue for 2027 to be $11,917,783,734, with the lowest DYN revenue forecast at $270,782,325, and the highest DYN revenue forecast at $38,981,450,007.

In 2028, DYN is forecast to generate $53,700,803,698 in revenue, with the lowest revenue forecast at $18,667,173,243 and the highest revenue forecast at $151,789,366,581.

What is DYN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: DYN) forecast ROA is -4.17%, which is lower than the forecast US Biotechnology industry average of 37.27%.

What is DYN's Price Target?

According to 6 Wall Street analysts that have issued a 1 year DYN price target, the average DYN price target is $37.50, with the highest DYN stock price forecast at $50.00 and the lowest DYN stock price forecast at $24.00.

On average, Wall Street analysts predict that Dyne Therapeutics's share price could reach $37.50 by Jul 31, 2027. The average Dyne Therapeutics stock price prediction forecasts a potential upside of 45.91% from the current DYN share price of $25.70.

What is DYN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: DYN) Dyne Therapeutics's current Earnings Per Share (EPS) is -$3.30. On average, analysts forecast that DYN's EPS will be -$3.10 for 2026, with the lowest EPS forecast at -$3.39, and the highest EPS forecast at -$2.92. On average, analysts forecast that DYN's EPS will be -$2.95 for 2027, with the lowest EPS forecast at -$3.81, and the highest EPS forecast at -$2.38. In 2028, DYN's EPS is forecast to hit -$2.36 (min: -$4.30, max: -$0.89).

What is DYN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: DYN) forecast ROE is -5.91%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.